Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Urinary Bladder Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Glioblastoma 1Genomic Instability 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1Adenocarcinoma of Lung 1ALK-positive NSCLC 1ALK+ Advanced NSCLC 1ALK Gene Rearrangement Positive 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × alectinib × Clear all
NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

German Cancer Research Center

Phase 2 Completed
72 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡